
|Articles|May 1, 2004
Long-term outcome of juvenile dermatomyositis rests on early treatment with immunosuppresants
Washington -Timely diagnosis of juvenile dermatomyositis is critical because early, aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis, which is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














